The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics (Q44514327)

3 December 2017

The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics (English)

1 reference

complications of diabetes mellitus

3 December 2017

1 reference

BENEDICT Group

1

1 reference

PubMed ID

12865039

3 December 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Contemporary Clinical Trials

3 December 2017

1 reference

3 December 2017

24

1 reference

3 December 2017

4

1 reference

3 December 2017

442-461

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. Microalbuminuria Collaborative Study Group, United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Understanding the nature of renal disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Pathophysiology of Progressive Nephropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Excess mortality associated with diuretic therapy in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

Age of onset and type of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2803%2900028-X

7 January 2021

10.1016/S0197-2456(03)00028-X

Identifiers

DOI

1 reference

3 December 2017

1 reference

PubMed ID

12865039